Arena Pharmaceuticals Inc. (ARNA)

55.72
NASDAQ : Health Technology
Prev Close 52.88
Day Low/High 53.24 / 55.83
52 Wk Low/High 31.97 / 64.48
Avg Volume 517.80K
Exchange NASDAQ
Shares Outstanding 49.83M
Market Cap 2.63B
EPS -0.60
P/E Ratio 4.54
Div & Yield N.A. (N.A)
Arena Pharmaceuticals: Don't Fight the Tape or Jim Cramer's Evaluation

Arena Pharmaceuticals: Don't Fight the Tape or Jim Cramer's Evaluation

Let's see what the charts suggest for risk points.

Biotech Sector Steps Up to Provide Some Strong Action for Traders

Biotech Sector Steps Up to Provide Some Strong Action for Traders

The S&P 500 has shown the same pattern for three consecutive days.

Will the Market Go Dead for a While?

Will the Market Go Dead for a While?

The best way to deal with it is to keep on hunting for individual stocks.

The Headlines Are Wrong -- This Is an Extremely Bullish Market

The Headlines Are Wrong -- This Is an Extremely Bullish Market

It is two totally different markets when you compare the small-cap action to the big-cap indices.

Small-Caps Are the Place to Be for Now

Small-Caps Are the Place to Be for Now

We are seeing a focus on finding smaller names that may offer interesting valuations and stories.

Market Bifurcation: Individual Stocks Are Acting Better Than the Indices

Market Bifurcation: Individual Stocks Are Acting Better Than the Indices

This underperformance is being caused by pockets of weakness in bigger-cap names.

Reminder: Healthy Stock Markets Decline, Too

Reminder: Healthy Stock Markets Decline, Too

The key for the overall market now is that it hold above today's early lows.

Many Names on My Radar

Many Names on My Radar

There is no question that we are becoming extended and ripe for some profit taking.

Trump's Drug Pricing Plan Makes Me Want to Play Ball With Biotech Stocks

Trump's Drug Pricing Plan Makes Me Want to Play Ball With Biotech Stocks

Sector charts should shape up as worries about prices are finally put to rest.

Having Some Good Luck With Biotech Names

Having Some Good Luck With Biotech Names

Overall it is still a positive day but the action is sloppy.

Markets Make an Art of Unpredictability

Markets Make an Art of Unpredictability

Oil isn't the only reason stocks are higher.

Buffett's Apple Move Doesn't Do Much to Shift the Negative Technical Pattern

Buffett's Apple Move Doesn't Do Much to Shift the Negative Technical Pattern

Finding good setups in individual stocks is still challenging as there simply isn't a lot of strong momentum.

Smaller Companies Are Often Some of the Best Trading Vehicles

Smaller Companies Are Often Some of the Best Trading Vehicles

The challenge of this market is that the upward moves have not been well sustained.

3 Sectors I'm Trading Right Now as a Market Rotation Takes Hold

3 Sectors I'm Trading Right Now as a Market Rotation Takes Hold

Rotational action is the main theme Wednesday and good opportunities are out there.

My Biggest Concern About This Stock Market

My Biggest Concern About This Stock Market

There's a worrisome scenario that could develop this afternoon.

Here's When You Can Buy Twitter's Stock

Here's When You Can Buy Twitter's Stock

There just aren't any pockets of strong momentum right now.

Revance Therapeutics Soars on Phase 3 Data -- Biotech Movers

Revance Therapeutics Soars on Phase 3 Data -- Biotech Movers

The Newark, Calif.-based firm unveiled positive top-line results from a pair of studies evaluating RT002 for the treatment of glabellar, or frown, lines.

These Stocks Have Changed Direction

These Stocks Have Changed Direction

Finding bullish and bearish reversals in the market.

Playing Obesity Drugs the ETF Way

Playing Obesity Drugs the ETF Way

Liquidity is key, and one ETF stands above the rest.

Obesity Treatment Shift Could Aid Stocks

Obesity Treatment Shift Could Aid Stocks

Obesity costs are a  pain point, which  often create good investments.

Break With the Crowd

Break With the Crowd

At major market turns, it is invariably wrong.

The Next Big Thing in Biotech: J.P. Morgan Conference

The Next Big Thing in Biotech: J.P. Morgan Conference

Adam Feuerstein, senior columnist for TheStreet, says the coming week's J.P. Morgan Healthcare Conference is the next big thing in biotech.

The Next Big Thing In Biotech: 2013 Outlook

The Next Big Thing In Biotech: 2013 Outlook

Adam Feuerstein, Sr. Columnist for TheStreet, offers his outlook for the best and worst biotech stock in the coming year.

The Next Big Thing In Biotech: Best CEO Candidates

The Next Big Thing In Biotech: Best CEO Candidates

Adam Feuerstein, Sr. Columnist for TheStreet, is assembling candidates for the Best Biotech CEO of 2012 award.

Weight Loss Pills Not a Threat, Says Medifast CEO

Weight Loss Pills Not a Threat, Says Medifast CEO

Mike MacDonald, CEO of Medifast, says the company's new franchise strategy is propelling its stock and recently approved weight loss pills are not a threat.

The Next Big Thing in Biotech: Obesity Drugs

The Next Big Thing in Biotech: Obesity Drugs

Senior columnist Adam Feuerstein says obesity drugs are the next big thing to watch in biotech.

Stocks Under $10: Stealth Drug Play

Stocks Under $10: Stealth Drug Play

Portfolio manager David Peltier finds a pharmaceutical name that is quietly growing faster than its peers.

The Next Big Thing in Biotech: FDA Approvals

The Next Big Thing in Biotech: FDA Approvals

Senior columnist Adam Feuerstein says post-FDA approval trading is the next big thing to watch in biotech.

A Trifecta of Wrong

How else can we explain these post-market moves on OK earnings?